News Releases Year None2023202220212020201920182017 NuCana to Present at the Jefferies 2019 London Healthcare Conference Nov 14, 2019 NuCana Reports Third Quarter 2019 Financial Results and Provides Business Update Nov 13, 2019 NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 29, 2019 NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Oct 25, 2019 NuCana to Present at the Morgan Stanley 17th Annual Global Healthcare Conference Aug 29, 2019 NuCana to Participate in Citi’s 14th Annual Biotech Conference Aug 27, 2019 NuCana Reports Second Quarter 2019 Financial Results and Provides Business Update Aug 21, 2019 Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Aug 20, 2019 NuCana Announces First Patients Dosed in Phase I Study of NUC-7738 Jul 17, 2019 NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer Jun 12, 2019 Pagination First page « first Previous page ‹ previous … Page 4 Page 5 Page 6 Page 7 Current page 8 Page 9 Page 10 Page 11 Page 12 Next page next › Last page last »
NuCana Presents Data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics Oct 29, 2019
NuCana Announces FDA Clearance to Commence Phase III Study of Acelarin (NUC-1031) for the First-Line Treatment of Patients with Biliary Tract Cancer Oct 25, 2019
Enrollment in the Independent Investigator-Sponsored Phase III Metastatic Pancreatic Study ACELARATE Has Been Suspended Following a Prespecified Futility Analysis Aug 20, 2019
NuCana Receives Orphan Drug Designation from the U.S. Food and Drug Administration for Acelarin® for the Treatment of Biliary Tract Cancer Jun 12, 2019